Index of Contributors

Ackerman, R. H., 10–40
Altman, H. J., 496–498
Aporti, F., 504–506
Arnsten, A. F. T., 218–234

Bäckman, L., 255–268, 523–524
Bartus, R. T., 332–358, 515–517
Beall, S., 469–470
Bellini, F., 504–506
Berry, S. D., 525–527
Bjorklund, A., 536–537
Bloom, F. E., 194–202
Bleecker, M. L., 499–501
Boast, C. A., 450–452
Bolla-Wilson, K., 499–501
Bonetti, A. C., 504–506
Brandt, J., 460–462, 502–503
Brown, M., 528–530
Bushnell, P. J., 513–514

Calderini, G., 504–506
Caris, K., 469–470
Chrobak, J. J., 538–540
Church, R. M., 453–456
Clegg, R. A., 10–40
Cohen, N. J., 10–40, 54–71, 510–512, 533–535
Cork, L. C., 287–295
Corkin, S., xi–xiii, 10–40, 54–71, 457–459, 533–535
Coyle, J., 518–519
Crane, S., 494–495
Crawford, J. D., 457–459
Crook, T., 428–436, 515–517
Cumin, R., 482–484

Dantzer, R. D., 194–202
Davies, P., 212–217
Davis, H. P., 492–493
DeAcedo, B. S., 54–71
Dean, R. L., 332–358, 515–517
DeHaven, D. L., 538–540
Demediuk, P., 469–470
de Toledo-Morrell, L., 296–311
Deweer, B., 507–509

Eichenbaum, H., 54–71, 510–512
Evans, J. L., 513–514, 531–532

Fagan, A., 510–512
Ferris, S., 515–517
Flicker, C., 332–358, 515–517

Gabrieli, J. D. E., 457–459
Gage, F. H., 536–537
Gamzu, E., xi–xiii, 370–393, 482–484, 489–491
Goldman-Rakic, P. S., 218–234
Graves, C. A., 486–488
Growdon, J. H., 533–535
Grunberger, J., 406–427

Hanin, I., 538–540
Hardy, J., 255–268
Heller, J. R., 499–501
Hepler, D., 518–519
Horrocks, L., 469–470
Huff, F. J., 437–449

Ingram, D. K., 312–331
Ivanuš, J., 543–546
Iwata, J., 463–464
Izquierdo, I., 162–177

Jarrard, L. E., 520–522
Jones, R. S. G., 394–405

Kant, G. J., 520–522
Keim, K., 482–484
Kesner, R. P., 122–136
Kitt, C. A., 287–295
Kohl, D., 460–462
Koob, G. F., 194–202

Lassen, G., 502–503
Lebrun, C., 194–202
LeDoux, J. E., 463–464
Le Moal, M., 194–202
Levy, S., 520–522

Mactutus, C. F., 465–468
Martinez, J. L., 194–202
Mathisen, K. S., 528–530
Mazziotta, J. C., 269–286
McClelland, J. L., 1–9
McGaugh, J. L., 150–161
Meck, W. H., 453–456
Mervis, R., 469–470
Meyer, D. R., 469–470
Meyerhoff, J. L., 520–522
Morrell, F., 296–311
Moscovitch, M., 78–96
Murphy, D. E., 450–452

Naber, E., 469–470
Netto, C. A., 162–177
Nilsson, L.-G., 255–268, 523–524

Olin, D. A., 471–474
Oliver, C. G., 525–527
Olpe, H.-R., 394–405
Olton, D. A., xi–xiii, 113–121, 494–495, 518–519, 536–537
Orosz, A., 543–546

Pettinati, H. M., 528–530
Pontecorvo, M. J., 332–358, 513–514, 531–532
Pontius, A. A., 475–477
Price, D. L., 287–295
Pulsinelli, W. A., 492–493

Rakić, Lj., 543–546
Reis, D. J., 463–464
Riley, A. L., 471–474
Rosen, T. J., 10–40
Routtenberg, A., 203–211
Rubinsky, E., 502–503

Sagar, H. J., 533–535
Sakaguchi, A., 463–464
Saletu, B., 406–427
Samorajski, T., 478–481
Sara, S. J., 178–193, 507–509
Schacter, D. L., 41–53
Schwam, E., 482–484
Schwartz, G. E., 485
Sepinwall, J., 482–484
Shapiro, M. L., 536–537
Simon, D., 536–537
Smith, R. C., 478–481
Solomon, P. R., 486–488
Squire, L. R., 137–149
Steinmann, M. W., 394–405
Stenevi, U., 536–537
Struble, R. G., 287–295
Sullivan, E. V., 10–40

Taylor, J. D., 513–514
Teolato, S., 504–506
Thal, L. J., 235–241
Tilson, H. A., 538–540
Toffano, G., 504–506

Van Hoeson, G. W., 97–112
Verderese, A., 489–491
Vincent, G., 489–491
Volpe, B. T., 492–493
Vroulis, G. A., 478–481

Walker, L. C., 287–295
Wallace, L., 469–470
Walsh, T. J., 538–540
Warrington, E. K., 72–77
Weingartner, H., 359–369
Wenk, G., 518–519, 541–542
Whitehouse, P. J., 287–295
Wilde, C. G., 494–495
Winblad, B., 255–268
Wise, N. M., 465–468

Zanotti, A., 504–506
Zola-Morgan, S., 137–149
Zornetzer, S. F., 242–254

Subject Index

AF64A, *see* Ethylcholine aziridinium ion
Age differences, avoidance of, in single-trial free recall, 523–524
Age-related impairments, analysis of, 312–328
Aging
  effect on learning curves, 499–501
  memory and, psychological aspects of, 255–259
  memory dysfunctions associated with, 516–517
  memory loss and, electrophysiological markers of, 296–307
  normal
    biochemical changes in, 259–261
    brain biochemistry in, 255–265
    neurophysiological aspects of, 407–410
Alaproclate, mediation of storage and retrieval with, 496–497
Alcoholic men, spatial aspects of memory implicated in face drawings of, 475–476
Alzheimer's disease
  acetylcholine in, 262
  basal forebrain cholinergic system in, 290
  changes in cerebrospinal fluid associated with, 235–251
  clinical drug trials in, 428–433
  dopamine and, 264
  hippocampus and, 130–133
  noradrenaline and, 263
  piracetam plus lecithin trials in, 478–480
  positron computed tomography and, 276–277
  prefrontal cortex and, 133–135
  search for models of, 450
  serotonin and, 263–264
Amnesia
  after ischemic cerebral injury, 492–493
  anterograde, 6, 72
  basic aspects of, 6–8
  bitemporal, 6–7
  developing memory systems and their relation to, 84–86
  disconnection analysis of, 72–76
  global, of different etiologies, analysis of, 10–37
  intact priming in, 48–51
  malingered, detecting, 502–503
  preserved learning abilities in, 510–512
  relation of distributed models of cognitive processes to, 6–8
  retrograde, 6
Amnestic syndromes, position computed tomography and, 281–282
Amygdala, 100–104
  involvement in memory modulation, 155–157
Aneurysm of the ACoA, *see* Anterior communicating artery aneurysms
Animal behavioral models in discovery of compounds to treat memory dysfunction, 370–388
Animal models
  of environmentally induced memory impairment, 513–514
  of human memory impairments, development of, 113–119
  validity of, 151
Animals, impairment and enhancement of memory in, 151–152
Aniracetam
  effects on enhancement and protection of memory, 489–491
  effects on primate behavior and EEG, 482–483
  effects upon delayed matching-to-sample performance of monkeys and pigeons, 531–532
Anoxia, cerebral, as cause of global amnesia, 15–16
Anterior communicating artery aneurysms, ruptured saccular, as cause of global amnesia, 11, 13, 14
Anterograde memory impairments, 360
Anticholinergics, effects of, 212–213
Antihypoxidotic/nootropic drugs
  neurophysiological aspects in proving therapeutic efficacy of, 421–423
  pharmaco-EEG profiles of, 417
  relationship between neurophysiological and behavioral changes after, 420
Appetitive classical conditioning, 525–527
Arginine vasopressin, 194–199
  antagonists, 196
  behavioral actions of, 195–196
  behavioral mechanism of action for, 197–198
  innoculates against age-related changes in temporal memory, 453–455
  physiological actions of, 194
  stress and, 198–199
Attention, selective, noradrenergic modulation of, 178–191
Attentional dysfunctions, 361
Auditory emotional memories, 463–464

Automatic encoding deficit in amnesia of Korsakoff's syndrome, 460–462

Basal forebrain cholinergic system, 287–291
  anatomy of, 288
  consequences of experimental lesions of the, 289–290
  effects of aging on, 288–289
  physiology of, 288
β-Endorphin, role in behavioral regulation, 162–174
Benzodiazepine receptor, 363–364
Bilateral medial temporal-lobe resection, as cause of global amnesia, 17, 19
Brain transplants, 536–537

Catecholamines
  age-related cognitive decline and, 225–228
  anatomical distribution in primate neocortex, 218, 222
  cognitive decline in aged nonhuman primates and, 218–232
  involvement in age-related memory dysfunction, 242–251
  relationship to cognitive function, 222–224
Cerebral metabolism, human, 269–283
Cerebrospinal fluid, changes in, associated with dementia, 235–251
Choline-containing diets, chronic, neurobehavioral effects of, 469–470
Cholinergic hypothesis, history and future of, 332–350
Cholinergic lesions, memory dysfunctions associated with, 516–517
Cholinergic neuron, 366–367
Cholinergic system
  basal forebrain, *see* Basal forebrain cholinergic system
  role of, in human memory and cognition, 212–215
  status of, in disorders with memory dysfunction, 213–214
Classical conditioning
  appetitive, 525–527
  of nictitating membrane response in aged rabbits, 486–487
Closed-head injury, as cause of global amnesia, 14–15
Cognition, role of cholinergic system in, 212–215
Cognitive decline, catecholamines and, 218–232
Cognitive dysfunctions
  models of types of, 362–367
  process specific, 361
Cognitive impairments without subjective awareness, 362
Cognitive processes, distributed models of, *see* Distributed models of cognitive processes
Conditioned reflex responses, GABA effect on, in teleost, 543–546
Confounding variation, 314
Consolidation, memory, 138–139

Dementia
  changes in cerebrospinal fluid associated with, 235–251
  neurophysiological aspects of, 410–417
  positron computed tomography and, 276–281
  senile, *see* Senile dementia
Depressed geriatric patients, memory complaints of, 528–530
Diets, chronic choline-containing, neurobehavioral effects of, 469–470
Discrimination, simple delayed, in rat, 471–474
Distributed models of cognitive processes, 1–9
  appeal of, reasons for, 4–5
  basic characteristics of, 1–2
  processing as an interactive process, 3
  relation to amnesia, 6–8
  relation to physiology, 5–6
Dopamine, Alzheimer's disease and, 264
Dorsomedial thalamic nucleus, 106–108
Down's syndrome, basal forebrain cholinergic system in, 290
Drug trials, clinical, in Alzheimer's disease, 428–433

Effort (cognitive capacity) demanding processes, impairments in, 360–361
Electrophysiological markers of aging and memory loss in rats, 296–307
Electrophysiological method for examining effects of potential therapeutic agents on memory function, 494–495
Encephalitis, herpes simplex, as cause of global amnesia, 16–17
Encoding deficit, automatic, in amnesia of Korsakoff's syndrome, 460–462
Encoding operations, incomplete, 364–365
Encoding-rehearsal dysfunctions, 361
Engram, 465–468
Episodic memory failures, 360
Ethylcholine aziridinium ion (AF64A), 538–540
  intracerebral injections of, 520–522

Forebrain
  basal, memory and, 118–119
  non-human primate, neural systems of, implicated in memory, 97–109

Forgetting, alleviation by pretest contextual cueing in rats, 507–509
Free recall, single trial, avoidance of age differences in, 523–524

GABA effect on conditioned reflex responses in teleost, 543–546
Gamma, 7
Geriatric Evaluation by Relative's Rating Instrument, 485
Geriatric inpatients, depressed memory complaints in, 528–530
Global memory impairments of different etiologies, analyses of, 10–37

Herpes simplex encephalitis, as cause of global amnesia, 16–17
Hippocampal formation, 98–100
Hippocampus
  Alzheimer's disease and the, 130–133
  animal, 124–127
  human, 123–124
Human cerebral metabolism, 269–283
Huntington's disease, positron computed tomography and, 279

Impairments, age-related analysis of, 312–328
Infant memory, theories of, 79–80
Ischemic cerebral injury, amnesia after, 492–493

Kindling, spatial, effect of pentoxifylline on, 301–305
Knowledge
  acquisition of, different memory systems underlying, 54–70
  priming of, in amnesic patients and normal subjects, 41–51
Korsakoff's syndrome
  as cause of global amnesia, 17
  automatic encoding deficit in amnesia of, 460–462

Learning curves, effect of aging on, 499–501
Lecithin, plus piracetam, in senile dementia, 478–480
Locus coeruleus as target for psychogeriatric agents, 394–404
Long-term memory trace, 3–4

Malingered amnesia, uncovering, 502–503
Maze performance, complex, analysis of, 315–325
Memory
  aging and, psychological aspects of, 255–259
  basal forebrain and, 118–119
  basic concepts in, 2–4
  complaints in depressed geriatric inpatients, 528–530
  consolidation, failures in, 362
  enhancement of, in animals, 151–152
  from infancy to old age, 78–94
  hormonal modulation of, 152–155
  impairment of, in animals, 151–152
  infant, theories of, 79–80
  neural systems of forebrain implicated in, 97–109
  neuropsychology of, 137–147
  phosphoprotein regulation of, 203–209
  protein kinase C regulation of, 203–209
  remote, dissociations among processes in, 533–535
  role of cholinergic system in, 212–215
  spatial, effect of pentoxifylline on, 301–305
  spatial aspects of, implicated in face drawings of alcoholic men, 475–476
  temporal, arginine vasopressin innoculates against age-related changes in, 453–455
  two kinds of, 139–140
Memory dysfunction
  adrenergic involvement in, 158–159
  age-dependent, pharmacological effect of phosphatidylserine on, 504–506
  age-related, catecholamine system involvement in, 242–251
  animal behavior models in discovery of compounds to treat, 370–388
  associated with aging, cholinergic lesions, and senile dementia, 515–517
  clinical evaluation of compounds for treatment of, 437–447
  models of, 359–367
  vigilance and, 406–424
Memory function, electrophysiological method for examining effects of potential therapeutic agents on, 494–495
Memory impairment
  environmentally induced, animal models of, 513–514
  human, development of animal models of, 113–119
Memory-learning failures, varieties of, 360–362
Memory loss, age-related, electrophysiological markers of, 296–307
Memory retrieval, noradrenaline and, 183–190

Memory storage, modulation of, 150–159
Memory systems, different, underlying acquisition of knowledge, 54–70
Metabolism, human cerebral, 269–283
Models
  animal, *see* Animal models
  animal behavior, in discovery of compounds to treat memory dysfunction, 370–388
Modulation
  of memory storage, 150–159
  noradrenergic, of selective attention, 178–191
Monkeys
  aged, pharmacological treatment of, 228–231
  delayed matching-to-sample performance of, effects of aniracetam on, 531–532

Neural systems of forebrain implicated in memory, 97–109
Neuron, cholinergic, 366–367
Neuropsychology of memory, 137–147
Nictitating membrane response, classical conditioning of, in aged rabbits, 486–487
Nonverbal memory processes, human, influence of sex steroids on, 457–459
Noradrenaline, memory retrieval and, 183–190
Nucleus basalis magnocellularis, lesions in, 518–519
Nucleus basalis of Meynert, 104–106

Parkinson's disease, basal forebrain cholinergic system in, 290
Parahippocampal gyrus, 98
Pentoxifylline, effects on spatial memory kindling and potentiation, 301–305
Pharmacotherapy for cognitive deficits in nonhuman primates, 224–225
Phosphatidylcholine, 441–447
Phosphatidylserine, pharmacological effect on age-dependent memory dysfunction, 504–506
Physiology, relation of distributed models to, 5–6
Pigeons, delayed matching-to-sample performance of, effects of aniracetam on, 531–532
Piracetam, 441–447
  plus lecithin trials in senile dementia, 478–480
Pirenperone, mediation of storage and retrieval with, 496–497
Positron computed tomography, 269–283
  studies in patients, 274–283
    with dementia, 276–281
    with pure amnestic syndromes, 281–282
  studies of normal subjects with, 270–274
Potentiation, effect of pentoxifylline on, 304
Prefrontal cortex
  Alzheimer's disease and, 133–135
  animals and, 128–130
  human, 127–128
Preserved learning abilities, 510–512
Primates
  aged nonhuman, catecholamines and cognitive decline in, 218–232
  basal forebrain cholinergic system in, 287–291
Priming of knowledge in amnesic patients and normal subjects, 41–51
Psychopharmacology, geriatric, family member reports in, 485

Rabbits, aged, classical conditioning of nictitating membrane response in, 486–487
Rats
  alleviation of forgetting by pretest contextual cueing in, 507–509
  electrophysiological markers of aging and memory loss in, 296–307
  simple delayed discrimination in, 471–474
Remote memory, dissociations among processes in, 533–535
Retention performance, 465–468
Retrieval failures, 362

Sampling, 313–314
Selective attention, noradrenergic modulation of, 178–191
Senile dementia
  biochemical findings in, 261–264
  memory dysfunctions associated with, 516–517
  memory function and brain biochemistry in, 255–265
  piracetam plus lecithin trials in, 478–480
Serotonin, Alzheimer's disease and, 263–264
Sex steroids, influence on human nonverbal memory processes, 457–459
Stress, vasopressin and, 198–199
Stroke, bilateral, as cause of global amnesia, 17
Substantia innominata, pharmacological manipulation of the, 541–542

Teleost, conditioned reflex responses in, GABA effect on, 543–546
Temporal attributes, coding of, 122–135
Temporal memory, age-related changes in, arginine vasopressin inoculates against, 453–455

Therapeutic agents, potential, electrophysiological method for examining effects on memory function, 494–495
Tomography, positron, computed, 269–283
Tower of Hanoi puzzle, 57–69
Transplants, brain, 536–537
Turner's syndrome, 457–459

Variation, confounding, 316
Vasopressin, *see* Arginine vasopressin
Vigilance, memory dysfunctions and, 406–424

Word completion task, priming of new information in, 42–45

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES

Volume 444

May 30, 1985

Memory Dysfunctions: An Integration of Animal and Human Research from Preclinical and Clinical Perspectives[a]

Editors

DAVID S. OLTON, ELKAN GAMZU, and SUZANNE CORKIN

CONTENTS

Introduction. *By* DAVID S. OLTON, ELKAN GAMZU, and SUZANNE CORKIN xi

Session I. Human Neuropsychology. *Chair,* LARRY R. SQUIRE

Distributed Models of Cognitive Processes: Applications to Learning and Memory. *By* JAMES L. MCCLELLAND 1

Analyses of Global Memory Impairments of Different Etiologies. *By* SUZANNE CORKIN, NEAL J. COHEN, EDITH V. SULLIVAN, RAY ANN CLEGG, T. JOHN ROSEN, and ROBERT H. ACKERMAN 10

Priming of Old and New Knowledge in Amnesic Patients and Normal Subjects. *By* DANIEL L. SCHACTER 41

Different Memory Systems Underlying Acquisition of Procedural and Declarative Knowledge. *By* NEAL J. COHEN 54

A Disconnection Analysis of Amnesia. *By* ELIZABETH K. WARRINGTON 72

Memory From Infancy to Old Age: Implications for Theories of Normal and Pathological Memory. *By* MORRIS MOSCOVITCH 78

Neural Systems of the Non-human Primate Forebrain Implicated in Memory. *By* GARY W. VAN HOESEN 97

Session II. Animal Models of Amnesic Syndromes. *Chair,* SUZANNE CORKIN

Strategies for the Development of Animal Models of Human Memory Impairments. *By* DAVID S. OLTON 113

Correspondence between Humans and Animals in Coding of Temporal Attributes: Role of Hippocampus and Prefrontal Cortex. *By* RAYMOND P. KESNER 122

The Neuropsychology of Memory: New Links between Humans and Experimental Animals. *By* L. R. SQUIRE and S. ZOLA-MORGAN 137

[a]The papers in this volume were presented at a conference entitled Memory Dysfunctions: An Integration of Animal and Human Research from Preclinical and Clinical Perspectives, which was held by the New York Academy of Sciences on June 13–15, 1984.

Session III. Biochemistry of Memory. ***Chair,*** **DONALD PRICE**

Peripheral and Central Adrenergic Influences on Brain Systems Involved in the Modulation of Memory Storage. *By* JAMES L. MCGAUGH 150

Role of β-Endorphin in Behavioral Regulation. *By* IVAN IZQUIERDO and CARLOS A. NETTO 162

Noradrenergic Modulation of Selective Attention: Its Role in Memory Retrieval. *By* SUSAN J. SARA 178

Arginine Vasopressin, Stress, and Memory. *By* GEORGE F. KOOB, CHRISTINE LEBRUN, JOE L. MARTINEZ, JR., ROBERT D. DANTZER, MICHEL LE MOAL, and FLOYD E. BLOOM 194

Phosphoprotein Regulation of Memory Formation: Enhancement and Control of Synaptic Plasticity by Protein Kinase C and Protein Fl. *By* ARYEH ROUTTENBERG 203

A Critical Review of the Role of the Cholinergic System in Human Memory and Cognition. *By* PETER DAVIES 212

Session IV. Neurobiological Markers of Memory Loss. ***Chair,*** **LEON J. THAL**

Catecholamines and Cognitive Decline in Aged Nonhuman Primates. *By* AMY F. T. ARNSTEN and PATRICIA S. GOLDMAN-RAKIC 218

Changes in Cerebrospinal Fluid Associated with Dementia. *By* LEON J. THAL 235

Catecholamine System Involvement in Age-Related Memory Dysfunction. *By* STEVEN F. ZORNETZER 242

Memory Function and Brain Biochemistry in Normal Aging and in Senile Dementia. *By* BENGT WINBLAD, JOHN HARDY, LARS BÄCKMAN, and LARS-GORAN NILSSON 255

Human Cerebral Metabolism: Studies in Normal Subjects and Patients with Dementia and Amnesia. *By* JOHN C. MAZZIOTTA 269

The Functional Organization of the Basal Forebrain Cholinergic System in Primates and the Role of this System in Primates in Alzheimer's Disease. *By* DONALD L. PRICE, LINDA C. CORK, ROBERT G. STRUBLE, PETER J. WHITEHOUSE, CHERYL A. KITT, and LARRY C. WALKER 287

Session V. Amnesia and Aging. ***Chair,*** **JOHN H. GROWDON**

Electrophysiological Markers of Aging and Memory Loss in Rats. *By* LEYLA DE TOLEDO-MORRELL and FRANK MORRELL 296

Analysis of Age-Related Impairments in Learning and Memory in Rodent Models. *By* DONALD K. INGRAM 312

The Cholingergic Hypothesis: A Historical Overview, Current Perspective, and Future Directions. *By* RAYMOND T. BARTUS, REGINALD L. DEAN, MICHAEL J. PONTECORVO, and CHARLES FLICKER 332

Models of Memory Dysfunctions. *By* HERBERT WEINGARTNER 359

Session VI. Pharmacological Strategies in the Treatment of Memory Loss. ***Chair,*** **RAYMOND T. BARTUS**

Animal Behavioral Models in the Discovery of Compounds To Treat Memory Dysfunction. *By* ELKAN GAMZU 370

Locus Coeruleus as a Target for Psychogeriatric Agents. *By* HANS-RUDOLF OLPE, MARTIN W. STEINMANN, and ROLAND S. G. JONES 394

Psychopharmacological Aspects. *By* B. SALETU and J. GRUNBERGER..... 406

Clinical Drug Trials in Alzheimer's Disease. *By* THOMAS CROOK 428

Clinical Evaluation of Compounds for the Treatment of Memory Dysfunction. *By* J. H. GROWDON, S. CORKIN, and F. J. HUFF 437

Poster Papers

Searching for Models of Alzheimer's Disease: A Comparison of Four Amnestic Treatments in Two Behavioral Tasks. *By* D. E. MURPHY and C. A. BOAST. 450

Arginine Vasopressin Inoculates Against Age-Related Changes in Temporal Memory. *By* WARREN H. MECK and RUSSELL M. CHURCH..... 453

The Influence of Sex Steroids on Human Nonverbal Memory Processes. *By* J. D. E. GABRIELI, S. CORKIN, and J. D. CRAWFORD 457

An Automatic Encoding Deficit in the Amnesia of Korsakoff's Syndrome. *By* DEBORAH KOHL and JASON BRANDT 460

Auditory Emotional Memories: Establishment by Projections from the Medial Geniculate Nucleus to the Posterior Neostriatum and/or Dorsal Amygdala. *By* JOSEPH E. LEDOUX, AKIRA SAKAGUCHI, JIRO IWATA, and DONALD J. REIS..... 463

The Inaccessible, But Intact Engram: A Challenge for Animal Models of Memory Dysfunction. *By* CHARLES F. MACTUTUS and NANCY M. WISE.... 465

Neurobehavioral Effects of Chronic Choline-Containing Diets on the Adult and Aging C57BL/GNNIA Mouse Brain. *By* RONALD MERVIS, LLOYD HORROCKS, PAUL DEMEDIUK, LANE WALLACE, DONALD R. MEYER, SUSAN BEALL, KIMBERLY CARIS, and EDWARD NABER 469

Simple Delayed Discrimination in the Rat: A Behavioral Baseline. *By* DEBORAH A. OLIN and ANTHONY L. RILEY 471

Spatial Aspects of Memory Implicated in Face Drawings of Alcoholic Men. *By* ANNELIESE A. PONTIUS..... 475

Piracetam Plus Lecithin Trials in Senile Dementia of the Alzheimer Type (SDAT). *By* T. SAMORAJSKI, G. A. VROULIS, and R. C. SMITH..... 478

The Effects of Aniracetam on Primate Behavior and EEG. *By* ELIAS SCHWAM, KEVIN KEIM, RUDI CUMIN, ELKAN GAMZU, and JERRY SEPINWALL 482

Family Member Reports in Geriatric Psychopharmacology. *By* GERRI E. SCHWARTZ 485

Classical Conditioning of the Nictitating Membrane Response in Aged Rabbits. *By* PAUL R. SOLOMON and CYNTHIA A. GRAVES 486

The Effects of Aniracetam (Ro 13-5057) on the Enhancement and Protection of Memory. *By* GEORGE VINCENT, ANTHONY VERDERESE, and ELKAN GAMZU..... 489

Amnesia in Humans and Animals After Ischemic Cerebral Injury. *By* BRUCE T. VOLPE, WILLIAM A. PULSINELLI, and HASKER P. DAVIS..... 492

An Electrophysiological Method for Examining the Effects of Potential Therapeutic Agents on Memory Function. *By* CYNTHIA G. WILDE, SHARON CRANE, and DAVID S. OLTON 494

Mediation of Storage and Retrieval with Two Drugs that Selectively Modulate Serotonergic Neurotransmission. *By* HARVEY JAY ALTMAN 496

The Effect of Aging on Learning Curves. *By* M. L. BLEECKER, K. BOLLA-WILSON, and J. R. HELLER 499

Uncovering Malingered Amnesia. *By* JASON BRANDT, ELIZABETH RUBINSKY, and GEORGE LASSEN 502

Pharmacological Effect of Phosphatidylserine on Age-Dependent Memory Dysfunction. *By* G. CALDERINI, F. APORTI, F. BELLINI, A. C. BONETTI, S. TEOLATO, A. ZANOTTI, and G. TOFFANO 504

Alleviation of Forgetting by Pretest Contextual Cueing in Rats. *By* BERNARD DEWEER and SUSAN J. SARA 507

Normal Learning Set and Facilitation of Reversal Learning in Rats with Combined Fornix-Amygdala Lesions: Implications for Preserved Learning Abilities in Amnesia. *By* A. FAGAN, H. EICHENBAUM, and N. COHEN 510

Animal Models of Environmentally Induced Memory Impairment. *By* H. L. EVANS, P. J. BUSHNELL, M. J. PONTECORVO, and J. D. TAYLOR 513

Animal and Human Memory Dysfunctions Associated with Aging, Cholinergic Lesions, and Senile Dementia. *By* CHARLES FLICKER, REGINALD DEAN, RAYMOND T. BARTUS, STEVEN FERRIS, and THOMAS CROOK 515

Lesions in Nucleus Basalis Magnocellularis and Medial Septal Area of Rats Produce Similar Memory Impairments in Appetitive and Non-appetitive Behavioral Tasks. *By* D. HEPLER, G. WENK, D. OLTON, and J. COYLE 518

Intracerebral Injections of AF64A: An Animal Model of Alzheimer's Disease? *By* LEONARD E. JARRARD, SHARON LEVY, JAMES L. MEYERHOFF, and G. JEAN KANT 520

The Avoidance of Age Differences in Single-Trial Free Recall. *By* LARS BÄCKMAN and LARS-GORAN NILSSON 523

Morphine-Induced Disruption of Behavioral but not Hippocampal Conditioned Responses During Appetitive Classical Conditioning. *By* CELIA G. OLIVER and STEPHEN D. BERRY 525

Memory Complaints in Depressed Geriatric Inpatients. *By* HELEN M. PETTINATI, MARIE BROWN, and KENNETH S. MATHISEN 528

Effects of Aniracetam upon the Delayed Matching-to-Sample Performance of Monkeys and Pigeons. *By* M. J. PONTECORVO and H. L. EVANS 531

Dissociations Among Processes in Remote Memory. *By* H. J. SAGAR, N. J. COHEN, S. CORKIN, and J. H. GROWDON 533

Brain Transplants: Can They Restore Single Unit Activity in the Hippocampus? *By* M. L. SHAPIRO, D. SIMON, D. S. OLTON, F. H. GAGE, A. BJORKLUND, and U. STENEVI 536

AF64A Produces Long-Term Cognitive Impairments Following Infusion into the Lateral Cerebral Ventricles or the Dorsal Hippocampus: Involvement of Hippocampal Cholinergic Processes in Learning and Memory. *By*

THOMAS J. WALSH, JAMES J. CHROBAK, HUGH A. TILSON, DIANE L. DEHAVEN, and ISRAEL HANIN 538
Pharmacological Manipulation of the Substantia Innominata–Cortical Cholinergic Pathway. *By* G. L. WENK 541
GABA Effect on Conditioned Reflex Responses in Teleost. *By* J. IVANUŠ, A. OROSZ, and L. RAKIĆ 543
Index of Contributors 547
Subject Index 549

Financial assistance received from:

- American Cyanamid Company (Lederle Laboratories)
- Bristol-Myers/Pharmaceutical Research and Development Division
- Burroughs Wellcome Co.
- CIBA-GEIGY/Pharmaceuticals Division
- E.I. du Pont de Nemours & Company/Biomedical Products Department
- Fidia Research Laboratories
- Glaxo Group
- Hoechst-Roussel Pharmaceuticals Inc.
- Hoffmann-La Roche Inc.
- Lilly Research Laboratories
- Merck Sharp & Dohme/Research Laboratories
- Office of Naval Research
- Pfizer/Central Research
- Sandoz Pharmaceuticals
- Schering-Plough Corporation
- Searle Research and Development/Division of G. D. Searle & Co.
- Stuart Pharmaceuticals/Division of ICI Americas Inc.
- Warner Lambert Company

The New York Academy of Sciences believes that it has a responsibility to provide an open forum for discussion of scientific questions. The positions taken by the authors of the papers that make up this *Annal* are their own and not those of the Academy. The Academy has no intent to influence legislation by providing such forums.